youtube_live
Q3 2026 earnings • released • EPS beat +6.86% • Revenue beat +2.01%
See resultschevron_right
DVA:NYSE
Davita Inc
$185.74
arrow_downward
-1.02%(-1.91) 1D
$185.74
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 2, 4:00:04 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DVA...
Open
$186.38
High
$186.38
Low
$180.40
Mkt. cap
11.68B
Avg. vol.
706.75K
Volume
1.00
P/E ratio
13.68
52-wk high
$247.49
52-wk low
$101.00
EPS
$13.58
Beta
0.80
Shares outstanding
62.90M
No. of employees
78K
Open
$186.38
High
$186.38
Low
$180.40
Mkt. cap
11.68B
Avg. vol.
706.75K
Volume
1.00
P/E ratio
13.68
52-wk high
$247.49
52-wk low
$101.00
EPS
$13.58
Beta
0.80
Shares outstanding
62.90M
No. of employees
78K
News stories
From web sources and news partners
Investing.com
·
23 hours ago
UBS raises DaVita stock price target to $287 on reimbursement outlook
Yahoo Finance
·
1 day ago
What Does DaVita (DVA) Stock Risk From The HHS Reform Probe?
Yahoo Finance
·
2 days ago
DVA Q3 deep dive: technology investment and integrated care strategy drive guidance shift
Yahoo Finance
·
3 days ago
DaVita Inc. Q3 2026 Earnings Call Summary
Profile
DaVita Inc. is an American health care company, incorporated in Delaware and headquartered in Denver, that provides kidney dialysis services through a network of 2,657 outpatient centers in the United States. DaVita serves 200,500 patients, and has 585 outpatient centers in 14 other countries serving 94,500 patients. The company primarily treats end-stage renal disease, which requires patients to undergo kidney dialysis, often 3 times per week for the rest of their lives unless they receive a kidney transplant via organ donation.
In 2025, 68% of the company's revenues came from Medicare and other government-based health insurance programs. In 2025, 89% of the company's patients were covered by government-based health insurance programs. Commercial payers, which accounted for 32% of revenues in 2025, generate nearly all of the company's profit as they reimburse at a much higher rate than government-based health insurance programs. The company is ranked 331st on the 2026 Fortune 500. Wikipedia
About Davita Inc
CEOJavier J. Rodriguez
Employees78K
Founded1992
HeadquartersDenver, Colorado, United States
SectorHealth care provider
Websitedavita.com
Analyst ratings
Based on 6 analysts giving stock ratings to DVA in the past 3 months
Buy
Buy
3
Hold
2
Sell
1
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for DVA in the last 3 months.
Highest
Current $185.74
$287.00 (+54.52%)
Average
$231.83 (+24.81%)
Lowest
$180.00 (-3.09%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Ryan Langston TD Cowen | Buy | Reiterated | $228.00 | +22.8% | 11/02/2026 |
A.J. Rice UBS | Buy | Maintained | $287.00 | +54.5% | 11/02/2026 |
Andrew Mok CFA Barclays | Hold | Maintained | $216.00 | +16.3% | 11/02/2026 |
Kevin Fischbeck Bank of America Securities | Sell | Reiterated | $180.00 | -3.1% | 10/30/2026 |
David S Macdonald Truist Financial | Hold | Maintained | $215.00 | +15.8% | 08/11/2026 |
Pito Chickering Deutsche Bank | Buy | Reiterated | $265.00 | +42.7% | 08/05/2026 |
Last report
Oct 29, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
$3.82 / $3.57
+6.86%beat
arrow_upward
Revenue / Est. (USD)
3.58B / 3.51B
+2.01%beat
arrow_upward
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
Revenue | 3.62B | 3.42B | 3.55B | 3.58B |
Cost of goods sold | 2.41B | 2.34B | 2.39B | 2.45B |
Cost of revenue | 2.41B | 2.34B | 2.39B | 2.45B |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 472.36M | 421.91M | 423.46M | 408.70M |
Operating expense | 659.06M | 599.74M | 591.27M | 573.88M |
Total operating expenses | 3.07B | 2.94B | 2.98B | 3.02B |
Operating income | 551.20M | 473.55M | 570.82M | 553.19M |
Other non operating income | -21.03M | 639.00K | 4.47M | 5.63M |
EBT including unusual items | 382.76M | 341.23M | 435.01M | 358.71M |
EBT excluding unusual items | 391.79M | 341.23M | 437.04M | 420.88M |
Income tax expense | 76.73M | 66.20M | 91.79M | 89.32M |
Effective tax rate | 20.05% | 19.40% | 21.10% | 24.90% |
Other operating expenses | - | - | - | - |
Net income | 234.22M | 197.53M | 265.40M | 222.93M |
Net profit margin | 6.47% | 5.78% | 7.47% | 6.23% |
Earnings per share | 3.40 | 2.87 | 4.02 | 3.82 |
Interest and investment income | - | - | - | - |
Interest expense | -148.25M | -141.30M | -146.42M | -146.18M |
Net interest expenses | -148.25M | -141.30M | -146.42M | -146.18M |
Depreciation and amortization charges | 186.70M | 177.83M | 167.81M | 165.19M |
EBITDA | 737.91M | 651.38M | 738.62M | 718.38M |
Gain or loss from assets sale | -17.55M | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events